Memorial Hospital Research Laboratories

The Constantinos Sofocleous Lab

Research

Constantinos T. Sofocleous
Constantinos Sofocleous, MD, PhD

The Constantinos Sofocleous Lab focuses in the exploration, assessment, and validation of tissue and image biomarkers after local and locoregional therapies for metastatic colorectal cancer. The research staff includes experts in radiation physics, 3D software applications in medicine, histopathology and molecular cytology, immune response and cross-sectional and metabolic imaging. Ongoing collaborations with molecular cytology core lab, epidemiology and statistics, radiation safety and physics are crucial for the translational aspects of our research. Additional collaborators include clinical pathologists, computational laboratories, immunology experts bioengineers, interventional radiologists and medical oncologists.

Research Projects

2025 Lab Members

2025 Lab Members

2024 Lab Members

2024 Lab Members

2023 Lab Members

2023 Lab Members

Publications Highlights

Kitsel Y, Vakiani E, Kirov A, Zirakchian Zadeh M, Kunin H, Petre EN, Crane CH, Romesser P, Sotirchos VS, Sofocleous CT. Histopathologic Changes after Yttrium-90 Radioembolization of Colorectal Liver Metastases: A Pilot Feasibility Study. J Vasc Interv Radiol. 2024 Jul;35(7):1012-1021.e1. doi: 10.1016/j.jvir.2024.04.010. Epub 2024 Apr 24. PMID: 38670528. Histopathologic Changes after Yttrium-90 Radioembolization of Colorectal Liver Metastases: A Pilot Feasibility Study - PubMed

Three-Dimensional Margin as a Predictor of Local Tumor Progression after Microwave Ablation: Intraprocedural versus 4-8-Week Postablation Assessment https://pubmed.ncbi.nlm.nih.gov/38215818/

Systemic Immunological Changes After Yttrium-90 Radioembolization: A Pilot Prospective Observational Study-Clinical Insights https://pubmed.ncbi.nlm.nih.gov/39406871/

Voxel-Based Dosimetry Predicts Local Tumor Progression Post 90 Y Radiation Segmentectomy of Colorectal Liver Metastases https://pubmed.ncbi.nlm.nih.gov/39745670/

Tumor Absorbed Dose Predicts Survival and Local Tumor Control in Colorectal Liver Metastases Treated with 90Y Radioembolization https://pubmed.ncbi.nlm.nih.gov/40925975/

View All Publications

People

Constantinos T. Sofocleous

Constantinos Sofocleous, MD, PhD

  • Interventional radiologist Constantinos Sofocleous leads research in the optimization of image-guided therapies for colorectal cancer metastases.
  • MD, PhD, University of Athens School of Medicine (Greece)
[email protected]
Email Address
212-639-3379
Office Phone
View physician profile
Physician profile

Members

Timothy Cooke
Medical Student
Mohammad Elsayed
IR Fellow
Jon Heiselman
Research Scholar
Yulia Kitsel
Research Fellow
Henry Kunin
Henry Kunin
Clinical Research Supervisor
Amgad M. Moussa
Assistant Professor, Interventional Oncologist/Radiologist
Elena N. Petre
Senior Research Scientist
Vlasios S. Sotirchos
Assistant Professor, Interventional Oncologist/Radiologist
Dimitrios Xenos
Research Fellow
Dimitris Xenos
Dimitris Xenos
Research Fellow
Randy Yeh
Assistant Professor, Radiologist
Mahdi Zirakchian Zadeh
Senior Research Scientist

Achievements

  • SIR 2023 Medical Student Scholar (Timothy Cooke)
  • Outstanding Clinical Study award, the highest honor the JVIR awards for individual papers, 2022
  • NIH/NCI R21 Award: Tissue Examinations from ablated Liver Tumors (2009)
  • NIH/NCI R01 Optimizing Thermal Ablation for Colon Cancer Liver Metastases
  • IMRAS/BSX/SIRTEX Grants Correlation of Histopathological findings with Radiation Exposure Levels after Y90 Radioembolization of Hepatic Metastases
  • Ethicon Ablation Registry and Ablation assessment Grants
  • Society of Interventional Oncology Ablation with Confirmation of Colorectal Liver Metastases (ACCLAIM) Trial
  • General grant from the Society of Interventional Radiology (SIR) Foundation: Correlations of Tumor Absorbed Dose to Histopathologic Changes and Local Tumor Control

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

To learn more about compensation and benefits for postdoctoral researchers at MSK, please visit Resources for Postdocs

Research Fellow

Research position available in our Interventional Oncology Lab dedicated in the development and assessments of tissue and surrogate image biomarkers applied in image-guided therapies for metastatic colorectal disease.

Apply now

Get in Touch

Disclosures

Members of the MSK Community often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community. These activities outside of MSK further our mission, provide productive collaborations, and promote the practical application of scientific discoveries.

MSK requires doctors, faculty members, and leaders to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public. Not all disclosed interests and relationships present conflicts of interest. MSK reviews all disclosed interests and relationships to assess whether a conflict of interest exists and whether formal COI management is needed.

Constantinos Sofocleous discloses the following relationships and financial interests:

  • Immunophotonics, Inc.
    Professional Services and Activities (Uncompensated)
  • NeuWave Medical, Inc
    Professional Services and Activities
  • Terumo Medical Corporation
    Professional Services and Activities
  • Varian Medical Systems
    Professional Services and Activities

The information published here is a complement to other publicly reported data and is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2024 through disclosure submission in spring 2025). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].


View all disclosures